Jazz Pharmaceuticals PLC (JAZZ)
Stock Price Chart
Key Info
| Market Cap | 8.25B |
| Revenue (ttm) | 2.22B |
| Net Income (ttm) | 133.24M |
| Shares Out | 55.46M |
| EPS (ttm) | 2.36 |
| PE Ratio | 63.03 |
| Forward PE | 9.50 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 22, 2020 |
| Last Price | $148.75 |
| Previous Close | $145.39 |
| Change ($) | 3.36 |
| Change (%) | 2.31% |
| Day's Open | 148.26 |
| Day's Range | 146.03 - 149.60 |
| Day's Volume | 85,019 |
| 52-Week Range | 86.88 - 156.27 |
More Stats
| Market Cap | 8.25B |
| Enterprise Value | 8.80B |
| Earnings Date (est) | Nov 2, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 55.46M |
| Float | 53.40M |
| EPS (basic) | 2.37 |
| EPS (diluted) | 2.36 |
| FCF / Share | 15.69 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 1.59% |
| FCF Yield | 10.54% |
| Payout Ratio | n/a |
| Shares Short | 4.76M |
| Short Ratio | 4.18 |
| Short % of Float | 8.91% |
| Beta | 1.15 |
| PE Ratio | 63.03 |
| Forward PE | 9.50 |
| P/FCF Ratio | 9.49 |
| PS Ratio | 3.72 |
| PB Ratio | 2.65 |
| Revenue | 2.22B |
| Operating Income | 202.80M |
| Net Income | 133.24M |
| Free Cash Flow | 869.25M |
| Net Cash | -551.24M |
| Net Cash / Share | -9.94 |
| Gross Margin | 91.75% |
| Operating Margin | 9.15% |
| Profit Margin | 6.00% |
| FCF Margin | 39.22% |
| ROA | 7.04% |
| ROE | 4.35% |
| ROIC | 6.40% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,162 | 1,891 | 1,619 | 1,488 | 1,325 | 1,173 | 872 | 586 | 272 | 174 |
| Revenue Growth | 14.32% | 16.82% | 8.79% | 12.32% | 12.95% | 34.44% | 48.88% | 115.21% | 56.68% | - |
| Gross Profit | 2,034 | 1,769 | 1,509 | 1,383 | 1,222 | 1,055 | 770 | 508 | 258 | 160 |
| Operating Income | 532 | 615 | 529 | 592 | 508 | 196 | 340 | 198 | 128 | 57.79 |
| Net Income | 523 | 447 | 488 | 397 | 330 | 58.39 | 216 | 289 | 125 | 32.78 |
| Shares Outstanding | 56.75 | 59.98 | 60.02 | 60.50 | 61.23 | 59.75 | 58.30 | 56.64 | 41.50 | 36.34 |
| Earnings Per Share | 9.09 | 7.30 | 7.96 | 6.41 | 5.23 | 0.93 | 3.51 | 4.79 | 2.67 | 0.83 |
| EPS Growth | 24.52% | -8.29% | 24.18% | 22.56% | 462.37% | -73.5% | -26.72% | 79.4% | 221.69% | - |
| Operating Cash Flow | 776 | 799 | 693 | 592 | 532 | 408 | 288 | 250 | 152 | 58.87 |
| Capital Expenditures | -40.14 | -20.37 | -28.95 | -9.69 | -35.96 | -36.35 | -9.98 | -5.98 | -1.28 | -0.73 |
| Free Cash Flow | 736 | 779 | 664 | 583 | 496 | 371 | 278 | 244 | 150 | 58.14 |
| Cash & Equivalents | 1,077 | 825 | 601 | 426 | 989 | 684 | 637 | 387 | 158 | 45.19 |
| Total Debt | 1,758 | 1,596 | 1,581 | 2,030 | 1,188 | 1,342 | 550 | 457 | - | 48.04 |
| Net Cash / Debt | -681 | -772 | -980 | -1,604 | -200 | -658 | 86.53 | -69.57 | 158 | -2.85 |
| Assets | 5,539 | 5,203 | 5,124 | 4,800 | 3,333 | 3,339 | 2,238 | 1,966 | 254 | 136 |
| Liabilities | 2,428 | 2,446 | 2,411 | 2,923 | 1,734 | 1,968 | 943 | 845 | 60.79 | 105 |
| Book Value | 3,111 | 2,757 | 2,713 | 1,877 | 1,599 | 1,371 | 1,296 | 1,121 | 193 | 30.55 |
Company Profile
Company Details
| Full Name | Jazz Pharmaceuticals PLC |
| Country | Ireland |
| Employees | 1,620 |
| CEO | Bruce C. Cozadd |
Stock Information
| Ticker Symbol | JAZZ |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: JAZZ |
| IPO Date | June 1, 2007 |
Description
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.